Mymetics: the power of a unique technology to develop next-generation vaccines and immunotherapies for infectious diseases, oncology and allergies
Our vaccines candidates against infectious diseases, like HIV, malaria, Chikungunya, RSV and Influenza are designed to induce protection against early transmission and infection, focusing both on the mucosal immune response as a first-line defence and the systemic humoral (blood) immune response, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Our vaccine candidates / immunotherapies for Oncology and Allergies are focused on triggering the right specific immune response, CD8+ and CD4+ Tcells for Oncology and no IgE and Th1 biased responses in Allergy treatments. Our virosome vaccine platform is being validated through partnerships with leading pharmaceutical, biotech and research organisations. Mymetics has received funds from the NIH, Bill and Melinda Gates Foundation, PATH-MVI, the European Union, the Swiss Research and Innovation Org. and financing through its main investors and through license and collaboration deals. Mymetics Corporation (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands. The company is registered in the US and trades on the OTCQB, a venture stage market place.